Analysts' Weekly Ratings Changes for Alexion Pharmaceuticals, Inc. (ALXN)LocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the th…
The GuardianHow a fish can teach us survivalThe Guardian1973 Transplants halted by the Department of Health because of poor survival rates so the BHF funds research into overcoming transplant rejection. 1976 BHF Professor Michael Davis demonstrates tha…
What's the Next Stop?Barron’sA number of its product candidates tackle autoimmune disorders, including rheumatoid arthritis and transplant rejection. Antoian says Maxygen has $5.77 a share in cash, yet the shares have been trading for just $6.00. H…
The Star-Ledger – NJ.comStock Investors Sell Off Shares of Bristol-Myers Squibb, Down 3.6%Financial News Network OnlineThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepati…
New Stock Ratings and Share Price Targets October 28thWall St. Cheat SheetThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatr…
Stocks Achieving 52-Week Highs as S&P 500 Surges Over 3%Wall St. Cheat SheetThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psy…
Selecta Announces $47.25 Million Financing to Broaden R&D Capabilities and …MarketWatch (press release)Examples for applications include autoimmune diseases, allergies and transplant rejection. Selecta's pipeline currently contains a vaccine …
Global Preventive and Therapeutic Vaccines Market Analysed to 2020 in New ReportMyCompanyPR (press release)The report also analyses therapeutic vaccines that target HIV, HCV, asthma and allergy, type 1 diabetes, multiple sclerosis, psoriasis, arthritis…
ABC Action NewsBristol-Myers Squibb Higher Ahead of EarningsTradersHuddle.comThe Company offers products and experimental therapies to address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and ps…
CITIGROUP RAISED ITS PT FOR BRISTOL-MYERS SQUIBB TO $40 (BMY)Zacks.com… manufactures and sells pharmaceutical and nutritional products. The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoi…